Year founded
-
Country of origin
Germany
HQ country
Germany
Total deal value
Average deal value
Company industry
- Healthcare & Pharmaceuticals
M&A expertise
- -
Industry expertise
- Healthcare & Pharmaceuticals
Affimed Therapeutics B.V. founded in 2000, a clinical-stage biopharmaceutical company. It focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. Affimed Therapeutics B.V. changed its name to Affimed N.V. on completion of its Nasdaq IPO in September 2014.
Latest deals
Public Shareholders acquires stake in Affimed N.V. from Affimed Shareholders
06-05-2015
€ 36.25 million